Conclusion
Our study demonstrated that the use of MTX resulted in liver tissue
damage, leading to both biochemical and histopathological changes.
However, RAN may be a promising alternative agent by activating the
antioxidant mechanism and suppressing the ROS mechanism in the liver.
RAN is a new antianginal agent with an antioxidant mechanism that
warrants further investigation. To our knowledge, this is the first
study to investigate the role of RAN in preventing and treating
MTX-induced liver damage. Our findings suggest that RAN may be a
potential hepatoprotective agent for future clinical applications.